Brett M. Hall
Chief Scientific OfficerDr. Brett M. Hall, Ph.D. serves as Chief Scientific Officer at Immuneering Corporation since November 2019. He also serves as the President, Founder and Chairman of the board of directors of Bioarkive, Inc., or Bioarkive and President and Founder of Trans Medical Sciences, LLC. He served as the Chief Executive Officer of Asellus Therapeutics, LLC from July 2015 until May 2018. He served as the Chief Executive Officer of Molecular Response, LLC. He served in roles of increasing responsibility with Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. He led the design, development and operation of a multi-million-dollar small animal imaging core facility at Nationwide Children's Hospital, the pediatric division of Ohio State University. He then transitioned to Janssen, LLC (the pharmaceutical division of J&J) where he led the European translational medicine group and patient-derived xenograft (PDX) biomarker efforts (Beerse, Belgium). He relocated, within J&J, to the U.S. in 2011 to head the Hematologic Oncology Disease Area Stronghold (Heme DAS) group, where he oversaw 8 clinical assets and helped register two drugs (siltuximab; an anti-IL-6 mAB and ibrutinib; a small molecule BTK inhibitor). He has over 35 publications and has been recognized for direct translational support and contributing to the successful acquisition and partnering of multiple drugs, including Ibrutinib (small molecule BTK inhibitor - multiple hematologic cancer indications), Daratumumab (anti-CD38 mAb - multiple myeloma) and CSL362 (anti-CD123 mAb – acute myeloid leukemia). In 2014, He transitioned to MedImmune (a subsidiary of AstraZeneca), where he led the Oncology Translational Medicine group with a portfolio of over 15 oncology drugs at various stages of clinical and pre-clinical development. He is a U.S. Air Force veteran and was Investment Banker (Series 6 and 63). He received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.
公司職務
- 公司名稱Immuneering Corporation股票代碼IMRX職務Chief Scientific Officer共事同僚
